These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3144700)

  • 21. Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study.
    Busch MP; Korelitz JJ; Kleinman SH; Lee SR; AuBuchon JP; Schreiber GB
    Transfusion; 1995; 35(11):903-10. PubMed ID: 8604486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nationwide ALT testing to prevent non-A, non-B hepatitis still on hold.
    Cowart VS
    JAMA; 1981 Dec; 246(24):2791-2. PubMed ID: 6796706
    [No Abstract]   [Full Text] [Related]  

  • 23. [Non-A, non-B viral hepatitis--study problems].
    Mikhaĭlov MI; Favorov MO; Kuznetsov SV
    Vopr Virusol; 1984; 29(4):389-99. PubMed ID: 6437078
    [No Abstract]   [Full Text] [Related]  

  • 24. Alanine aminotransferase cut-off values for blood donor screening using the new International Federation of Clinical Chemistry reference method at 37 degrees C.
    Brinkmann T; Dreier J; Diekmann J; Götting C; Klauke R; Schumann G; Kleesiek K
    Vox Sang; 2003 Oct; 85(3):159-64. PubMed ID: 14516445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Limited utility of alanine aminotransferase screening of hepatitis C antibody-screened blood donors.
    Cable R; Badon S; Pray C; Popovsky MA
    Transfusion; 1997 Feb; 37(2):206-10. PubMed ID: 9051097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Missed opportunities: ALT and anti-HBc as surrogate tests for hepatitis.
    Bettigole R; Shastri KA
    J Med; 1997; 28(5-6):363-9. PubMed ID: 9604794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of a table-top analyzer for predonation screening for alanine aminotransferase--a cost-effective approach?
    Saxena S; Endahl GL; Shulman IA
    Am J Clin Pathol; 1988 Sep; 90(3):296-9. PubMed ID: 3137804
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Testing the blood supply for non-A, non-B hepatitis. A nonspecific approach for improving transfusion safety has a heterogeneous impact on blood donors.
    Menitove JE
    Am J Clin Pathol; 1990 Apr; 93(4):589-91. PubMed ID: 2108581
    [No Abstract]   [Full Text] [Related]  

  • 29. Antibodies to hepatitis B core antigen in blood donors screened for alanine aminotransferase level and hepatitis non-A, non-B in recipients.
    Sugg U; Schenzle D; Hess G
    Transfusion; 1988; 28(4):386-8. PubMed ID: 3133848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence of non-A, non-B hepatitis after screening blood donors for antibodies to hepatitis C virus and surrogate markers.
    Barrera JM; Bruguera M; Ercilla MG; Sánchez-Tapias JM; Gil MP; Costa J; Gelabert A; Rodés J; Castillo R
    Ann Intern Med; 1991 Oct; 115(8):596-600. PubMed ID: 1909848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnosis of hepatitis C virus in Brazilian blood donors using a reverse transcriptase nested polymerase chain reaction: comparison with enzyme immunoassay and recombinant protein immunoblot assay.
    Gonçales NS; Costa FF; Vassallo J; Gonçales FL
    Rev Inst Med Trop Sao Paulo; 2000; 42(5):263-7. PubMed ID: 11058936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Significance of alanine aminotransferase and reduction of post-transfusion non-A, non-B hepatitis].
    Hoang B; Simonneau M; Le Xuan P; Guichoux P; Terrier E; Ruffie J
    Rev Fr Transfus Hemobiol; 1989 Apr; 32(2):93-106. PubMed ID: 2502996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alanine aminotransferase screening and hepatitis C virus antibody.
    Burckhardt JJ; Friedli H; Gardi A; Heiniger HJ
    Lancet; 1990 Aug; 336(8712):447-8. PubMed ID: 1974981
    [No Abstract]   [Full Text] [Related]  

  • 34. Safety of the blood supply. Surrogate testing and transmission of hepatitis C in patients after massive transfusion.
    Morris JA; Wilcox TR; Reed GW; Hunter EB; Wallas CH; Steane EA; Shotts SD; Vitsky JL
    Ann Surg; 1994 May; 219(5):517-25; discussion 525-6. PubMed ID: 7514394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reducing the incidence of non-A,non-B post-transfusion hepatitis by testing donor blood for alanine aminotransferase: economic considerations.
    Hornbrook MC; Dodd RY; Jacobs P; Friedman LI; Sherman KE
    N Engl J Med; 1982 Nov; 307(21):1315-21. PubMed ID: 6813736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening of blood donors.
    Carlson RE; Hering PJ
    JAMA; 1981 Sep; 246(11):1195. PubMed ID: 6790735
    [No Abstract]   [Full Text] [Related]  

  • 37. Rare detection of hepatitis B and hepatitis C virus genomes by polymerase chain reaction in seronegative donors with elevated alanine aminotransferase.
    Sankary TM; Yang G; Romeo JM; Ulrich PP; Busch MP; Rawal BD; Vyas GN
    Transfusion; 1994 Aug; 34(8):656-60. PubMed ID: 8073480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A study of hepatitis C virus antibodies and serum alanine amino transferase in blood donors in Hong Kong Chinese.
    Lin CK; Chu R; Li KB; Leong S
    Vox Sang; 1992; 62(2):98-101. PubMed ID: 1325715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum alanine aminotransferase in blood donors: activity distribution and effect of phenotype.
    Savage B; Sayers MH; Giblett ER
    Transfusion; 1982; 22(4):298-9. PubMed ID: 6808720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paradoxical marker of non-A, non-B hepatitis.
    Morris EM
    Ann Intern Med; 1986 Aug; 105(2):294. PubMed ID: 3089091
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.